デフォルト表紙
市場調査レポート
商品コード
1301123

CAR T細胞療法の市場規模、シェア、動向分析レポート:製品別(Abecma、Breyanzi)、適応疾患別(リンパ腫、白血病、多発性骨髄腫)、最終用途別、地域別、セグメント予測、2023年~2030年

CAR T-cell Therapy Market Size, Share & Trends Analysis Report by Product (Abecma, Breyanzi), By Disease Indication (Lymphoma, Leukemia, Multiple Myeloma), By End-use, By Region, And Segment Forecasts, 2023 - 2030

出版日: | 発行: Grand View Research | ページ情報: 英文 150 Pages | 納期: 2~10営業日

● お客様のご希望に応じて、既存データの加工や未掲載情報(例:国別セグメント)の追加などの対応が可能です。  詳細はお問い合わせください。

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=154.46円
CAR T細胞療法の市場規模、シェア、動向分析レポート:製品別(Abecma、Breyanzi)、適応疾患別(リンパ腫、白血病、多発性骨髄腫)、最終用途別、地域別、セグメント予測、2023年~2030年
出版日: 2023年06月23日
発行: Grand View Research
ページ情報: 英文 150 Pages
納期: 2~10営業日
  • 全表示
  • 概要
  • 図表
  • 目次
概要

CAR T細胞療法市場の成長と動向

Grand View Research, Inc.の最新レポートによると、世界のCAR T細胞療法市場規模は、2023年から2030年にかけて23.32%のCAGRで拡大し、2030年には159億7,000万米ドルに達すると予測されています。

CAR T細胞療法は、リンパ腫、多発性骨髄腫、白血病などの血液がんの治療において、患者の免疫系を利用してがん細胞を死滅させるというパラダイムシフトをもたらします。新興諸国における多発性骨髄腫などのがんの有病率の上昇が市場を牽引しています。製品承認や集中的な医薬品パイプラインという形で、規制当局のサポートが充実していることも、業界をさらに強化しています。例えば、米国国立医学図書館の2023年4月の発表によると、CAR T細胞に関連する約310の研究が、世界各地で初期第I相、第I相、第II相にわたって実施されています。

さまざまな企業が戦略的パートナーシップを結び、地理的な拡大とともに、世界中で治療をカバーする必要性に迫られています。そのため企業は、血液がんの潜在的な治療法や治療法へのアクセスがない国々で地理的な足跡を増やす戦略を採用しています。例えば、2022年8月31日、ギリアド傘下の医療企業カイトは、サウジアラビア、ブラジル、シンガポールでのCAR T細胞療法の拡大を発表しました。同社は、シンガポールで1000例以上の非ホジキンリンパ腫(NHL)の発生を報告し、サウジアラビアでは約1700例が診断されています。同様に、ブラジルでは毎年約12000例の非ホジキンリンパ腫が見つかっています。

COVID-19の大流行により、CAR T細胞療法を患者に実施することが困難になっており、特にパンデミックの初期には多くの病院や診療所がCOVID-19患者で溢れかえっていました。多くの病院は、COVID-19患者のためのリソースを確保するために、CAR T細胞療法を含む選択的治療を延期または中止しなければならなかっています。さらに、CAR T細胞療法にはサイトカイン放出症候群(CRS)などの重大な副作用があり、発熱、低血圧、COVID-19の症状を模倣した臓器障害を引き起こす可能性があるため、治療上の問題があっています。

さらに、発展途上国に出現した病院やがん治療センターでは、CAR T細胞の導入が進んでいます。これらのセンターは、費用と時間の効率的ながん治療が市場の全体的な成長を可能にするとして繁栄しています。例えば、2022年8月、メキシコのがん治療センターであるImmunotherapy Instituteは、米国とカナダの患者向けにCAR T細胞を提供する事業を開始しました。同様に、イスラエルでは、全プロセスを自社内で行うため、治療が約10日で完了し、顕著なコスト削減を実現しています。

新興国における熟練した専門家の不足と治療に伴う高コストが、市場成長の課題として残っています。しかし、認知度の向上と技術的に先進的なCAR T細胞療法に対する承認の増加は、これらの課題を軽減し、予測期間中の市場成長に貢献すると予想されます。Cancer Treatment Centers of Americaによると、2023年現在、6つのCAR T細胞療法が血液がんの治療薬として米国FDAに承認されています。

CAR T細胞療法市場レポートハイライト

  • 製品別では、2022年に43.76%のシェアを獲得したYescarta(axicabtagene ciloleucel)セグメントが市場を独占しました。Yescartaの高い使用率は、再発B細胞性大細胞リンパ腫に罹患した成人患者における好調なパフォーマンスと生存率の改善に起因しています。
  • 2022年の疾患別適応症では、リンパ腫が57.15%の最大シェアを占めました。同分野の市場浸透率が高いのは、世界的に同疾患の有病率が高いためです。加えて、CD-19抗原の除去に向けた市場プレイヤーの強力な製品フォーカスも成長を後押ししています。
  • 最終用途別では、病院セグメントが財政的・運営的リソースの強固な存在により、2022年に56.26%の大半のシェアを獲得しました。さらに、病院内ラボはプロセスを迅速化するため、高いシェアを獲得しています。
  • 北米は2022年に66.70%のシェアを獲得し、市場で圧倒的な地位を示しています。シェアが大きい主な理由は、迅速な承認と強固な医療保険適用により、患者数が多く、一般的かつ複雑なヘルスケアへの全体的なアクセスがあるためと考えられます。

目次

第1章 調査手法と範囲

  • 市場セグメンテーションと範囲
    • 市場の定義
  • 情報調達
    • 市場形成とデータの可視化
    • データの検証と公開
  • 調査の仮定
  • 調査手法
    • 購入したデータベース
    • GVRの内部データベース
    • 二次情報
    • 1次調査
    • 1次調査の詳細
  • 情報またはデータ分析
    • データ分析モデル
  • 市場の形成と検証
  • モデル詳細
    • 商品フロー分析
  • 二次情報のリスト
  • 世界市場:CAGR計算の目的

第2章 エグゼクティブサマリー

  • 市場スナップショット
  • セグメントのスナップショット
  • 競合情勢のスナップショット

第3章 市場変数、動向、および範囲

  • 市場系統の見通し
    • 親市場の見通し
    • 関連/補助的な市場見通し
  • 市場動向と展望
  • 市場力学
    • 市場促進要因分析
    • 市場抑制要因分析
  • 事業環境分析
    • SWOT分析:要因別(政治・法律、経済・技術)
    • ポーターのファイブフォース分析
    • COVID-19の影響分析

第4章 CAR T細胞療法市場:製品の推定・動向分析

  • 製品変動分析と市場シェア、2022年と2030年
  • 製品別
  • Abecma (idecabtagene vicleucel)
    • 世界のアベクマ(イデカブタゲン・ビクルセル)市場、2018年~2030年(100万米ドル)
  • Breyanzi (lisocabtagene maraleucel)
    • 世界のブレヤンジ(リソカブタゲン・マラロイセル)市場、2018年~2030年(100万米ドル)
  • Carvykti(ciltacabtagene autoleucel)
    • 世界カービクティ(シルタカブタゲンオートロイセル)の市場、2018-2030(100万米ドル)
  • Kymriah (tisagenlecleucel)
    • 世界のキムリア(チサゲンルクルーセル)市場、2018年~2030年(100万米ドル)
  • Tecartus(brexucabtagene autoleucel)
    • 世界のテカルタス(ブレクスカブタゲンオートロイセル)市場、2018~2030年(100万米ドル)
  • Yescarta(axicabtagene ciloleucel)
    • 世界の市場イエスカルタ(アキシカブタゲンシロロイセル)、2018-2030(100万米ドル)
  • その他
    • 世界のその他市場、2018~2030年(100万米ドル)

第5章 CAR T細胞療法市場:適応疾患の推定・動向分析

  • 適応疾患の変動分析と市場シェア、2022年および2030年
  • 疾患別
  • 白血病
    • 世界の白血病市場、2018年~2030年(100万米ドル)
  • リンパ腫
    • 世界のリンパ腫市場、2018-2030(100万米ドル)
  • 多発性骨髄腫
    • 多発性骨髄腫の世界市場、2018年~2030年(100万米ドル)

第6章 最終用途ビジネス分析

  • 最終用途の変動分析と市場シェア、2022年と2030年
  • 最終用途別
  • 病院
    • 病院市場、2018-2030(100万米ドル)
  • がん治療センター
    • がん治療市場、2018年~2030年(100万米ドル)

第7章 地域ビジネス分析

  • CAR T細胞療法市場:地域展望
  • 北米
    • 北米のCAR T細胞療法市場推計・予測、2018年から2030年(100万米ドル)
    • 米国
    • カナダ
  • 欧州
    • 欧州のCAR T細胞療法市場推計・予測、2018年から2030年(100万米ドル)
    • ドイツ
    • 英国
  • アジア太平洋地域
    • アジア太平洋地域のCAR T細胞療法市場推計・予測、2018年から2030年(100万米ドル)
    • 日本
    • 中国
  • 世界のその他の地域
    • その他の世界のCAR T細胞療法市場推計・予測、2018年から2030年(100万米ドル)

第8章 競合情勢

  • 会社の分類
  • 戦略マッピング
  • 企業プロファイル・一覧表
    • Bristol-Myers Squibb Company
    • Novartis AG
    • Gilead Sciences Inc
    • Bluebird Bio Inc
    • Johnson &Johnson Services Inc
    • Merck &Co.
    • Sorrento Therapeutics Inc
    • Sangamo Therapeutics
    • GSK Plc.
    • JW Therapeutics(Shanghai)Co., Ltd.
図表

List of Tables

  • Table 1 List of Abbreviations
  • Table 2 Global CAR T-cell therapy market, by product, 2018 - 2030 (USD Million)
  • Table 3 Global CAR T-cell therapy market, by disease indication, 2018 - 2030 (USD Million)
  • Table 4 Global CAR T-cell therapy market, by end-use, 2018 - 2030 (USD Million)
  • Table 5 Global CAR T-cell therapy market, by region, 2018 - 2030 (USD Million)
  • Table 6 North America CAR T-cell therapy market, by country, 2018 - 2030 (USD Million)
  • Table 7 North America CAR T-cell therapy market, by product, 2018 - 2030 (USD Million)
  • Table 8 North America CAR T-cell therapy market, by disease indication, 2018 - 2030 (USD Million)
  • Table 9 North America CAR T-cell therapy market, by end-use, 2018 - 2030 (USD Million)
  • Table 10 U.S. CAR T-cell therapy market, by product, 2018 - 2030 (USD Million)
  • Table 11 U.S. CAR T-cell therapy market, by disease indication, 2018 - 2030 (USD Million)
  • Table 12 U.S. CAR T-cell therapy market, by end-use, 2018 - 2030 (USD Million)
  • Table 13 Canada CAR T-cell therapy market, by product, 2018 - 2030 (USD Million)
  • Table 14 Canada CAR T-cell therapy market, by disease indication, 2018 - 2030 (USD Million)
  • Table 15 Canada CAR T-cell therapy market, by end-use, 2018 - 2030 (USD Million)
  • Table 16 Europe CAR T-cell therapy market, by country, 2018 - 2030 (USD Million)
  • Table 17 Europe CAR T-cell therapy market, by product, 2018 - 2030 (USD Million)
  • Table 18 Europe CAR T-cell therapy market, by disease indication, 2018 - 2030 (USD Million)
  • Table 19 Europe CAR T-cell therapy market, by end-use, 2018 - 2030 (USD Million)
  • Table 20 Germany CAR T-cell therapy market, by product, 2018 - 2030 (USD Million)
  • Table 21 Germany CAR T-cell therapy market, by disease indication, 2018 - 2030 (USD Million)
  • Table 22 Germany CAR T-cell therapy market, by end-use, 2018 - 2030 (USD Million)
  • Table 23 UK CAR T-cell therapy market, by product, 2018 - 2030 (USD Million)
  • Table 24 UK CAR T-cell therapy market, by disease indication, 2018 - 2030 (USD Million)
  • Table 25 UK CAR T-cell therapy market, by end-use, 2018 - 2030 (USD Million)
  • Table 26 UK CAR T-cell therapy market, by end-use, 2018 - 2030 (USD Million)
  • Table 27 Rest of Europe CAR T-cell therapy market, by product, 2018 - 2030 (USD Million)
  • Table 28 Rest of Europe CAR T-cell therapy market, by disease indication, 2018 - 2030 (USD Million)
  • Table 29 Rest of Europe CAR T-cell therapy market, by end-use, 2018 - 2030 (USD Million)
  • Table 30 Asia Pacific CAR T-cell therapy market, by country, 2018 - 2030 (USD Million)
  • Table 31 Asia Pacific CAR T-cell therapy market, by product, 2018 - 2030 (USD Million)
  • Table 32 Asia Pacific CAR T-cell therapy market, by disease indication, 2018 - 2030 (USD Million)
  • Table 33 Asia Pacific CAR T-cell therapy market, by end-use, 2018 - 2030 (USD Million)
  • Table 34 China CAR T-cell therapy market, by product, 2018 - 2030 (USD Million)
  • Table 35 China CAR T-cell therapy market, by disease indication, 2018 - 2030 (USD Million)
  • Table 36 China CAR T-cell therapy market, by end-use, 2018 - 2030 (USD Million)
  • Table 37 Japan CAR T-cell therapy market, by product, 2018 - 2030 (USD Million)
  • Table 38 Japan CAR T-cell therapy market, by disease indication, 2018 - 2030 (USD Million)
  • Table 39 Japan CAR T-cell therapy market, by end-use, 2018 - 2030 (USD Million)
  • Table 40 Rest of Asia-Pacific CAR T-cell therapy market, by product, 2018 - 2030 (USD Million)
  • Table 41 Rest of Asia-Pacific CAR T-cell therapy market, by disease indication, 2018 - 2030 (USD Million)
  • Table 42 Rest of Asia-Pacific CAR T-cell therapy market, by end-use, 2018 - 2030 (USD Million)
  • Table 43 Rest of World CAR T-cell therapy market, by product, 2018 - 2030 (USD Million)
  • Table 44 Rest of World CAR T-cell therapy market, by disease indication, 2018 - 2030 (USD Million)
  • Table 45 Rest of World CAR T-cell therapy market, by end-use, 2018 - 2030 (USD Million)

List of Figures

  • Fig. 1 Market research process
  • Fig. 2 Information procurement
  • Fig. 3 Primary research pattern
  • Fig. 4 Market research approaches
  • Fig. 5 Value chain-based sizing & forecasting
  • Fig. 6 Market formulation & validation
  • Fig. 7 CAR T-cell Therapy sequencing market segmentation
  • Fig. 8 Market snapshot, 2022
  • Fig. 9 Market trends & outlook
  • Fig. 10 Market driver relevance analysis (current & future impact)
  • Fig. 11 Market restraint relevance analysis (current & future impact)
  • Fig. 12 Swot analysis, by factor (political & legal, economic and technological)
  • Fig. 13 Porter's five forces analysis
  • Fig. 14 Market penetration & growth prospect mapping, 2022
  • Fig. 15 Global CAR T-cell therapy: product movement analysis
  • Fig. 16 Global CAR T-cell therapy, for Abecma, 2018 - 2030 (USD million)
  • Fig. 17 Global CAR T-cell therapy, for Breyanzi, 2018 - 2030 (USD million)
  • Fig. 18 Global CAR T-cell therapy, for Carvykti, 2018 - 2030 (USD million)
  • Fig. 19 Global CAR T-cell therapy, for Kymriah, 2018 - 2030 (USD million)
  • Fig. 20 Global CAR T-cell therapy, for Tecartus, 2018 - 2030 (USD million)
  • Fig. 21 Global CAR T-cell therapy, for Yescarta, 2018 - 2030 (USD million)
  • Fig. 22 Global CAR T-cell therapy: disease indication movement analysis
  • Fig. 23 Global CAR T-cell therapy, for leukaemia, 2018 - 2030 (USD million)
  • Fig. 24 Global CAR T-cell therapy, for lymphoma, 2018 - 2030 (USD million)
  • Fig. 25 Global CAR T-cell therapy, for multiple myeloma, 2018 - 2030 (USD million)
  • Fig. 26 Global CAR T-cell therapy: end-use movement analysis
  • Fig. 27 Global CAR T-cell therapy, for hospitals, 2018 - 2030 (USD million)
  • Fig. 28 Global CAR T-cell therapy, for cancer treatment centers, 2018 - 2030 (USD million)
  • Fig. 29 Regional marketplace: key takeaways
  • Fig. 30 Regional outlook, 2022 & 2030
  • Fig. 31 Global CAR T-cell therapy: region movement analysis
  • Fig. 32 North America CAR T-cell therapy, 2018 - 2030 (USD million)
  • Fig. 33 U.S. CAR T-cell therapy, 2018 - 2030 (USD million)
  • Fig. 34 Canada CAR T-cell therapy, 2018 - 2030 (USD million)
  • Fig. 35 Europe CAR T-cell therapy, 2018 - 2030 (USD million)
  • Fig. 36 Germany CAR T-cell therapy, 2018 - 2030 (USD million)
  • Fig. 37 UK CAR T-cell therapy, 2018 - 2030 (USD million)
  • Fig. 38 Rest of Europe CAR T-cell therapy, 2018 - 2030 (USD million)
  • Fig. 39 Asia Pacific CAR T-cell therapy, 2018 - 2030 (USD million)
  • Fig. 40 Japan CAR T-cell therapy, 2018 - 2030 (USD million)
  • Fig. 41 China CAR T-cell therapy, 2018 - 2030 (USD million)
  • Fig. 42 Rest of Asia Pacific CAR T-cell therapy, 2018 - 2030 (USD million)
  • Fig. 43 Rest of World CAR T-cell therapy, 2018 - 2030 (USD million)
目次
Product Code: GVR-4-68040-090-4

CAR T-cell Therapy Market Growth & Trends

The global CAR T-cell therapy market size is expected to reach USD 15.97 billion by 2030, expanding at 23.32% CAGR from 2023 to 2030, according to a new report by Grand View Research, Inc. CAR T-cell therapy presents a paradigm shift in the treatment of blood cancers such as lymphoma, multiple myeloma, and leukemia by utilizing the patient's immune system to terminate cancer cells. The rising prevalence of cancer types such as multiple myeloma in developing countries is driving the market. Rampant regulatory support in the form of product approvals and an intensive product pipeline of drugs further strengthens the industry. For instance, as per the U.S. National Library of Medicine April 2023, around 310 studies pertinent to CAR T-cells are being conducted across early phase I, phase I, and phase II in various parts of the world.

Various players are entering into strategic partnerships along with geographic expansion to necessitate therapy coverage across the world. Thereby, companies are adopting strategies to increase the geographical footprint in countries without access to potential cures or treatments for blood cancers. For instance, on August 31, 2022, Kite, a medical company operating under Gilead announced the expansion of CAR T-cell therapy in regions of Saudi Arabia, Brazil, and Singapore. The company reported an occurrence of 1000 or higher cases of non-Hodgkin lymphoma (NHL) in Singapore, while around 1700 cases of the disease are diagnosed in Saudi Arabia. Similarly, in Brazil, around 12000 cases of NHL are found each year.

The COVID-19 pandemic has made it difficult to administer CAR T-cell therapy to patients, particularly in the early stages of the pandemic when many hospitals and clinics were overwhelmed with COVID-19 patients. Many hospitals had to postpone or cancel elective procedures, including CAR T-cell therapy, to free up resources for COVID-19 patients. In addition, CAR T-cell therapy has significant side effects, including cytokine release syndrome (CRS), which can cause fever, low blood pressure, and organ damage which mimics the symptoms of COVID-19, thereby, curating problems to treat for condition.

Moreover, hospitals and cancer care centers emerging in developing countries are progressing with the adoption of CAR T-cells. These centers thrive as cost and time-efficient cancer treatments allow the market to grow holistically. For instance, in August 2022, Immunotherapy Institute, a cancer treatment center in Mexico began operations to offer CAR T-cells for American and Canadian patients. Similarly, in Israel, the therapy can be expedited in about 10 days owing to the entire process being conducted in-house, with notable cost reductions.

The lack of skilled professionals in emerging nations coupled with the high cost associated with the therapy remain challenges to market growth. However, rising awareness and increasing approvals for technologically advanced CAR T-cell therapy are anticipated to mitigate these challenges and contribute to market growth over the forecast period. According to Cancer Treatment Centers of America, six CAR T-cell therapies were approved by U.S. FDA for the treatment of blood cancers as of 2023.

CAR T-cell Therapy Market Report Highlights

  • By product, the Yescarta (axicabtagene ciloleucel) segment dominated the market with a share of 43.76% in 2022. The high usage of Yescarta can be attributed to strong performance and improved survivability in adults suffering from relapsed B-cell large lymphoma
  • Lymphoma accounted for the largest share of 57.15% in the disease indication segment in 2022. The high penetration of the market segment owes itself to the significant prevalence of the condition across the world. Additionally, the strong product focus by market players to eliminate the CD-19 antigen drives growth
  • By end-use, the hospital segment captured a majority share of 56.26% in 2022 due to the robust presence of fiscal and operational resources. Additionally, in-house labs for hospitals expedite the process faster, helping to gain a strong share
  • North America has shown a dominant position in the market with a 66.70% share in 2022. The primary reason for a sizable share can be attributed to the patient volume and overall access to general and complex healthcare, with speedy approvals and robust medical insurance coverage

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation and Scope
    • 1.1.1. Market definitions
      • 1.1.1.1. Product segment
      • 1.1.1.2. Disease indication segment
      • 1.1.1.3. End-use segment
  • 1.2. Information Procurement
    • 1.2.1. Market formulation & data visualization
    • 1.2.2. Data validation & publishing
  • 1.3. Research Assumptions
  • 1.4. Research Methodology
    • 1.4.1. Purchased database
    • 1.4.2. GVR's internal database
    • 1.4.3. Secondary sources
    • 1.4.4. Primary research
    • 1.4.5. Details of primary research
  • 1.5. Information or Data Analysis
    • 1.5.1. Data analysis models
  • 1.6. Market Formulation & Validation
  • 1.7. Model Details
    • 1.7.1. Commodity flow analysis
      • 1.7.1.1. Approach 1: Commodity flow approach
  • 1.8. List of Secondary Sources
  • 1.9. Global Market: CAGR CalculationObjectives

Chapter 2. Executive Summary

  • 2.1. Market Snapshot
  • 2.2. Segment Snapshot
  • 2.3. Competitive Landscape Snapshot

Chapter 3. Market Variables, Trends, & Scope

  • 3.1. Market Lineage Outlook
    • 3.1.1. Parent Market Outlook
    • 3.1.2. Related/Ancillary Market Outlook
  • 3.2. Market Trends and Outlook
  • 3.3. Market Dynamics
    • 3.3.1. Market Driver Analysis
      • 3.3.1.1. Growing cases of Cancer Malignancies across population
      • 3.3.1.2. Targeted treatment approach mitigates relapsed or refracted blood cancer cases.
      • 3.3.1.3. Robust product pipeline with regulatory approvals across geographies.
    • 3.3.2. Market Restraint Analysis
      • 3.3.2.1. High drug cost impedes the market growth
      • 3.3.2.2. Side-effects of CAR T-cell therapy
      • 3.3.2.3. Complex Manufacturing and Supply Chain
  • 3.4. Business Environment Analysis
    • 3.4.1. SWOT Analysis; By Factor (Political & Legal, Economic And Technological)
    • 3.4.2. Porter's Five Forces Analysis
    • 3.4.3. COVID-19 Impact Analysis

Chapter 4. CAR T-cell Therapy Market: Product Estimates & Trend Analysis

  • 4.1. Product Movement Analysis & Market Share, 2022 & 2030
  • 4.2. CAR T-cell Therapy Market Estimates & Forecast, By Product (USD Million)
  • 4.3. Abecma (idecabtagene vicleucel)
    • 4.3.1. Global Abecma (idecabtagene vicleucel) Market, 2018 - 2030 (USD Million)
  • 4.4. Breyanzi (lisocabtagene maraleucel)
    • 4.4.1. Global Breyanzi (lisocabtagene maraleucel) Market, 2018 - 2030 (USD Million)
  • 4.5. Carvykti (ciltacabtagene autoleucel)
    • 4.5.1. Global Carvykti (ciltacabtagene autoleucel) Market, 2018 - 2030 (USD Million)
  • 4.6. Kymriah (tisagenlecleucel)
    • 4.6.1. Global Kymriah (tisagenlecleucel) Market, 2018 - 2030 (USD Million)
  • 4.7. Tecartus (brexucabtagene autoleucel)
    • 4.7.1. Global Tecartus (brexucabtagene autoleucel) Market, 2018 - 2030 (USD Million)
  • 4.8. Yescarta (axicabtagene ciloleucel)
    • 4.8.1. Global Yescarta (axicabtagene ciloleucel) Market, 2018 - 2030 (USD Million)
  • 4.9. Others
    • 4.9.1. Global Others Market, 2018 - 2030 (USD Million)

Chapter 5. CAR T-cell Therapy Market: Disease Indication Estimates & Trend Analysis

  • 5.1. Disease Indication Movement Analysis & Market Share, 2022& 2030
  • 5.2. CAR T-cell Therapy Market Estimates & Forecast, By Disease Indication (USD Million)
  • 5.3. Leukemia
    • 5.3.1. Global Leukemia Market, 2018 - 2030 (USD Million)
  • 5.4. Lymphoma
    • 5.4.1. Global Lymphoma Market, 2018 - 2030 (USD Million)
  • 5.5. Multiple Myeloma
    • 5.5.1. Global Multiple Myeloma Market, 2018 - 2030 (USD Million)

Chapter 6. End-use Business Analysis

  • 6.1. End-use Movement Analysis & Market Share, 2022& 2030
  • 6.2. CAR T-cell Therapy Market Estimates & Forecast, By End-use (USD Million)
  • 6.3. Hospitals
    • 6.3.1. Hospitals Market, 2018 - 2030 (USD Million)
  • 6.4. Cancer Treatment Centers
    • 6.4.1. Cancer Treatment Market, 2018 - 2030 (USD Million)

Chapter 7. Regional Business Analysis

  • 7.1. CAR T-cell Therapy Market: Region Outlook
  • 7.2. North America
    • 7.2.1. North America CAR T-cell Therapy market estimates and forecast, 2018 - 2030 (USD Million)
    • 7.2.2. The U.S.
      • 7.2.2.1. Key Country Dynamics
      • 7.2.2.2. Competitive Scenario
      • 7.2.2.3. Regulatory Framework
      • 7.2.2.4. Disease Prevalence
      • 7.2.2.5. U.S. CAR T-cell therapy market estimates and forecast, 2018 - 2030 (USD Million)
    • 7.2.3. Canada
      • 7.2.3.1. Key Country Dynamics
      • 7.2.3.2. Competitive Scenario
      • 7.2.3.3. Regulatory Framework
      • 7.2.3.4. Disease Prevalence
      • 7.2.3.5. Canada CAR T-cell therapy market estimates and forecast, 2018 - 2030 (USD Million)
  • 7.3. Europe
    • 7.3.1. Europe CAR T-cell Therapy market estimates and forecast, 2018 - 2030 (USD Million)
    • 7.3.2. Germany
      • 7.3.2.1. Key Country Dynamics
      • 7.3.2.2. Competitive Scenario
      • 7.3.2.3. Regulatory Framework
      • 7.3.2.4. Disease Prevalence
      • 7.3.2.5. Germany CAR T-cell therapy market estimates and forecast, 2018 - 2030 (USD Million)
    • 7.3.3. UK
      • 7.3.3.1. Key Country Dynamics
      • 7.3.3.2. Competitive Scenario
      • 7.3.3.3. Regulatory Framework
      • 7.3.3.4. Disease Prevalence
      • 7.3.3.5. UK CAR T-cell therapy market estimates and forecast, 2018 - 2030 (USD Million)
  • 7.4. Asia Pacific
    • 7.4.1. Asia Pacific CAR T-cell Therapy market estimates and forecast, 2018 - 2030 (USD Million)
    • 7.4.2. Japan
      • 7.4.2.1. Key Country Dynamics
      • 7.4.2.2. Competitive Scenario
      • 7.4.2.3. Regulatory Framework
      • 7.4.2.4. Disease Prevalence
      • 7.4.2.5. Japan CAR T-cell therapy market estimates and forecast, 2018 - 2030 (USD Million)
    • 7.4.3. China
      • 7.4.3.1. Key Country Dynamics
      • 7.4.3.2. Competitive Scenario
      • 7.4.3.3. Regulatory Framework
      • 7.4.3.4. Disease Prevalence
      • 7.4.3.5. China CAR T-cell therapy market estimates and forecast, 2018 - 2030 (USD Million)
  • 7.5. Rest of World
    • 7.5.1. Rest of World CAR T-cell Therapy market estimates and forecast, 2018 - 2030 (USD Million)

Chapter 8. Competitive Landscape

  • 8.1. Company Categorization
  • 8.2. Strategy Mapping
  • 8.3. Company Profiles/Listing
    • 8.3.1. Bristol-Myers Squibb Company
      • 8.3.1.1. Overview
      • 8.3.1.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
      • 8.3.1.3. Product Benchmarking
      • 8.3.1.4. Strategic Initiatives
    • 8.3.2. Novartis AG
      • 8.3.2.1. Overview
      • 8.3.2.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
      • 8.3.2.3. Product Benchmarking
      • 8.3.2.4. Strategic Initiatives
      • 8.3.2.5. Overview
      • 8.3.2.6. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
      • 8.3.2.7. Product Benchmarking
      • 8.3.2.8. Strategic Initiatives
    • 8.3.3. Gilead Sciences Inc
      • 8.3.3.1. Overview
      • 8.3.3.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
      • 8.3.3.3. Product Benchmarking
      • 8.3.3.4. Strategic Initiatives
    • 8.3.4. Bluebird Bio Inc
      • 8.3.4.1. Overview
      • 8.3.4.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
      • 8.3.4.3. Product Benchmarking
      • 8.3.4.4. Strategic Initiatives
    • 8.3.5. Johnson & Johnson Services Inc
      • 8.3.5.1. Overview
      • 8.3.5.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
      • 8.3.5.3. Product Benchmarking
      • 8.3.5.4. Strategic Initiatives
    • 8.3.6. Merck & Co.
      • 8.3.6.1. Overview
      • 8.3.6.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
      • 8.3.6.3. Product Benchmarking
      • 8.3.6.4. Strategic Initiatives
    • 8.3.7. Sorrento Therapeutics Inc
      • 8.3.7.1. Overview
      • 8.3.7.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
      • 8.3.7.3. Product Benchmarking
      • 8.3.7.4. Strategic Initiatives
    • 8.3.8. Sangamo Therapeutics
      • 8.3.8.1. Overview
      • 8.3.8.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
      • 8.3.8.3. Product Benchmarking
      • 8.3.8.4. Strategic Initiatives
    • 8.3.9. GSK Plc.
      • 8.3.9.1. Overview
      • 8.3.9.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
      • 8.3.9.3. Product Benchmarking
      • 8.3.9.4. Strategic Initiatives
    • 8.3.10. JW Therapeutics (Shanghai) Co., Ltd.
      • 8.3.10.1. Overview
      • 8.3.10.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
      • 8.3.10.3. Product Benchmarking
      • 8.3.10.4. Strategic Initiatives